Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 8/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.36 |
| ▸ | ESRRA | P11474 | 3/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16541518 | 0.89 | KDM4E (0.40) | MGLLKDM4EALDH1A1CYP1A2HPGD | |
| SCHEMBL14464201 | 0.83 | ESR1 (0.43) | NR1H3KMT2AMEN1MAPTESR1 | |
| SCHEMBL10059426 | 0.83 | MGLL (0.44) | KMT2AMEN1MAPTMGLLTDP1 | |
| SCHEMBL10079855 | 0.83 | ALDH1A1 (0.41) | KMT2AMAPTMGLLKDM4EALDH1A1 | |
| SCHEMBL14532059 | 0.83 | ALDH1A1 (0.51) | MAPTPKMMGLLKDM4EALDH1A1 | |
| SCHEMBL146809 | 0.82 | ALDH1A1 (0.55) | KMT2AMEN1MAPTKDM4EALDH1A1 | |
| SCHEMBL10059425 | 0.81 | KMT2A (0.39) | KMT2AKDM4EALDH1A1ME2ME1 | |
| SCHEMBL141013 | 0.79 | CMA1 (0.44) | NR1H3MGLLKDM4EALDH1A1POLB | |
| SCHEMBL10059427 | 0.79 | ALDH1A1 (0.37) | KMT2AMEN1MAPK1KDM4EALDH1A1 | |
| SCHEMBL13263848 | 0.76 | ESR1 (0.38) | NR1H3KMT2AMEN1MAPTESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010536-B2 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170095462-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. | 2017-04-06 | — | — | US | disclosed |
| US-9527816-B2 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2591784-B1 | Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system | INTERMUNE INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20140228310-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8741936-B2 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2591784-A1 | Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system | Intermune, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| US-20120258924-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| EP-2426134-A2 | Method of modulating stress-activated protein kinase system | Intermune, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20120014917-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | UNIVERSITY OF MINNESOTA (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110218515-A1 | Methods for Treating Acute Myocardial Infarctions and Associated Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-08 | — | — | US | disclosed |
| WO-2010135470-A1 | PIFENIDONE DERIVATIVES FOR TREATING BRONCHIAL ASTHMA | INTERMUNE, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010132864-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | INTERMUNE, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100240704-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. | 2010-09-23 | — | — | US | disclosed |
| US-20100190731-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | INTERMUNE, INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010085805-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | INTERMUNE, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| US-7728013-B2 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| WO-2007062167-A9 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE INC (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007062167-A2 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190731-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | TNNI3, FABP3, TNNT2 | NR1H3 965/4885KMT2A 2633/4885MEN1 4281/4885 |
| US-20100240704-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | MAPKAPK2, MAP3K6, MAP4K1 | NR1H3 2846/4885KMT2A 4406/4885MEN1 4715/4885 |
| US-10010536-B2 | Method of modulating stress-activated protein kinase system | MAPKAPK2, MAP3K6, MAP4K1 | NR1H3 2846/4885KMT2A 4406/4885MEN1 4715/4885 |
| US-20170095462-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | MAPKAPK2, MAP3K6, MAP4K1 | NR1H3 2846/4885KMT2A 4406/4885MEN1 4715/4885 |
| US-20140228310-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | MAPKAPK2, MAP3K6, MAP4K1 | NR1H3 2846/4885KMT2A 4406/4885MEN1 4715/4885 |
| US-20120258924-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | MAPKAPK2, MAP3K6, MAP4K1 | NR1H3 2846/4885KMT2A 4406/4885MEN1 4715/4885 |
| US-20120014917-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | MMP1, MMP8, CCL11 | NR1H3 467/4885KMT2A 3685/4885MEN1 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.